May 21, 2021 -- Therapeutic Solutions International announced new data and a patent filing demonstrating that lithium carbonate augments the scar-inhibiting activity of its JadiCell universal donor stem cell therapy.
In double-blind, placebo-controlled clinical trial, JadiCell was successful at substantially improving survival in end-stage patients with acute lung failure associated with COVID-19. The treatment was associated with significantly improved patient survival, serious adverse event-free survival, and time to recovery.
The company plans to initiate a phase III pivotal registration trial and seek marketing approval for use of JadiCell in acute respiratory distress syndrome and other lung diseases.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
